Quality Comes First

COUNTRIES

CONTACT US

Our Pipeline and Products

Menarini is investing in advanced science and technology to develop a pipeline of new products that make a difference to the lives of patients affected by serious conditions.

Read more

MENARINI is a fully integrated privately owned pharma company with a long and successful heritage in strategic partnering across the globe. We have a profound know-how stemming from our strong R&D capabilities in key therapeutic areas, coupled with our excellence in commercial execution and our powerful direct presence on a global basis.

Share your partnering idea

Our dedicated Corporate Business Development team is committed to assess and explore innovative new opportunities.

 

Contact Us

Donations of backpacks and cases for school, distribution of meals and medicines, promotion of sport, support for pregnant women and much more: being responsible for Menarini means transforming good intentions into concrete efforts. By helping others, we want to contribute to improve the world around us, starting with us.

Our Values

Everyday we put our values into action. 4 values, which have given life to Menarini and shaped its history.

 

Read more

What does it really make Menarini unique? The diversity and authenticity of our key resource - the People.
Our cultural diversity helps us to drive innovation, adapt to business changes, face challenges, inspire ideas and develop our growth.

Available positions on Linkedin

Menarini employees make all the difference, every day.

 

Follow Us On Linkedin

News

2017-06-21

Menarini Ricerche to present the most recent data about the pre-clinical development of its novel ADC MEN1309/OBT076 at the 29th Pezcoller Symposium


Pomezia, June 21, 2017- Menarini Ricerche and the UK company Oxford BioTherapeutics (OBT) will present the latest data about their novel antibody drug-conjugate (ADC) MEN1309/OBT076, in development for solid and haematological tumors, at the 29th Pezcoller Symposium which will take place on June 22,23 2017 in Trento, Italy.

Results of the preclinical studies of the novel ADC, as well as the characterization of its target antigen Ly75/CD205, will be summarized in a poster entitled: “MEN1309/OBT076: a novel Antibody-Drug Conjugate targeting the Ly75/CD205 antigen”.

The poster will focus on the antitumor activity of MEN1309/OBT076 in vitro and in vivo. Indeed, MEN1309/OBT076 showed impressive anti-tumoral activity against NHL and triple negative breast cancer cell lines, in the corresponding xenograft models and in Patient-Derived Xenograft (PDX) models.

 

About MEN1309/OBT076

MEN1309/OBT076 is a fully humanized IgG1 monoclonal antibody conjugated to a potent cytotoxic maytansinoid toxin via a cleavable linker. The ADC is directed against a type I transmembrane glycoprotein and a C-type lectin receptor Ly75/ CD205, that is over-expressed in several solid tumors and non-Hodgking lymphomas (NHL). 

Fraud Warning Disclaimer

Please be aware that certain individuals might approach you by falsely presenting themselves as our employees, affiliates, agents or representatives. Under this false pretense, they might try to gain access to your personal information or to acquire money or other valuables from you by offering fictitious employment opportunities or by claiming that they are contacting you on our behalf. The contacting individual or organisation may, for example, claim that we can guarantee your employment if you pay them a certain amount of money. Such fraudulent offers and claims are usually received via email, the internet, text message, phone, etc. These claims and offers are fraudulent and invalid and you are strongly advised to exercise great caution when you receive such an offer of employment or notice. Be very mindful of such scams.Below we list some of the features such an offer or claim may have:

Below we list some of the features such an offer or claim may have:

• It may propose a phone or instant message program interview and/or money as a precondition for hiring You may be requested to disclose private, sensitive or confidential information

• You may be told that you were contacted in such a manner because it is a matter of urgency

Such an offer or claim will probably be in the form of an email sent from a fake email address or from a free email address and not from an official Menarini Group email address. Please take extra caution while examining such an email address, as the perpetrators may misspell an official Menarini Group email address and use a slightly modified version of an official Menarini Group email address.

Please note that you will never receive a fraudulent employment offer or any other similar claim from us, because we do not provide any recruitment services. Moreover, we will never ask you for money in exchange for employment opportunities or other similar services. Any such offer of employment or any other service in exchange for fees that claims to be from us is deceitful and part of a fraud.

Criminal and/or civil liabilities may arise from such actions and we intend to cooperate with competent law enforcement agencies. Accordingly, we would ask you to immediately get in touch with us upon receiving a suspicious offer or claim and additionally notify the police or other competent authority.

In any case, please disregard any written or oral request related to a job offer or an interview that you believe is or might be fraudulent or suspicious.

Please note that under no circumstances shall Menarini Group be held liable or responsible for any claims, losses, damages, expenses or other inconvenience resulting from or in any way connected to the actions of these imposters.